American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.

ABSTRACT:

Background

Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually identical methods, assessing whether American psychiatrists display greater optimism about the therapeutic use of hallucinogens in 2022-23.

Methods

We e-mailed our survey instrument to 1,000 randomly selected American Psychiatric Association members-250 resident-fellows and 750 attending psychiatrists-in late 2022 and early 2023. We calculated descriptive statistics and used

SUBMITTER: Barnett BS 

PROVIDER: S-EPMC11658671 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature